BC Extra | Nov 26, 2019
Politics & Policy

Pioneering FDA commissioner Frank Young dies at 88

Frank Young, who served as FDA Commissioner from 1984 to 1989, a pivotal and tumultuous era in drug regulation, died Nov. 24 at age 88. He was diagnosed last week with B Cell Lymphoma. Former...
BC Week In Review | Sep 14, 2018
Company News

ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of...
BC Extra | Sep 10, 2018
Company News

ICER finds opioid use disorder treatments are not cost-effective

In a draft evidence report , ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of...
BC Week In Review | May 4, 2018
Company News

ICER to consider broad outcomes for buprenorphines

In a draft scoping document published April 26, ICER said it will consider a broad set of outcomes in its review of three buprenorphine products as medication-assisted treatments for opioid use disorder. ICER is poised...
BC Extra | Apr 27, 2018
Politics & Policy

ICER to consider broad outcomes for buprenorphines

In a draft scoping document published Thursday, ICER said it will consider a broad set of outcomes in its review of three buprenorphine products as medication-assisted treatments for opioid use disorder. ICER is poised to...
BC Week In Review | Apr 6, 2018
Company News

ICER to evaluate buprenorphines for opioid disorder

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder. In...
BC Extra | Apr 5, 2018
Politics & Policy

ICER to evaluate buprenorphines for opioid disorder

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder. In...
BioCentury | Jul 6, 2017
Finance

Planting seeds

With a $1.5 billion open-ended fund, Apple Tree Partners is plowing large sums into a handful of translational start-ups with the goal of eventually having at least one portfolio company grow into a commercial-stage large...
BC Extra | Jun 1, 2017
Politics & Policy

NIH seeks public-private partnerships to fight opioid crisis

In an article published in the New England Journal of Medicine and a blog post , NIH Director Francis Collins and National Institute on Drug Abuse (NIDA) Director Nora Volkow outlined a plan to speed research...
BC Extra | Feb 2, 2017
Financial News

Braeburn cancels IPO plans

Braeburn Pharmaceuticals Inc. (Princeton, N.J.) said Thursday it has decided against conducting an IPO, citing market conditions. The company is the first biopharma this year to scuttle a planned IPO on NASDAQ. The company said...
Items per page:
1 - 10 of 78